FDA Teleconference for ME/CFS Stakeholders


FDA-logo-300x223Dear Colleagues:

The U.S. Food & Drug Administration (FDA) is pleased to invite you to a stakeholder teleconference between FDA and Myalgic Encephalomyelitis/Chronic Fatigue Syndrome (ME/CFS) patients and advocacy organizations on September 13, 2012. Dr. Janet Woodcock, Director of the Center of Drug Evaluation and Research, will lead the call. The purpose of the call is to discuss issues of mutual interest and concern including the lack of approved treatment options available for ME/CFS and how treatment development might be facilitated.

The teleconference is scheduled for Thursday, September 13, 2012 from 10:00 am – 11:30 am. Registration is required and must be received by September 7, 2012. Early registration is recommended because telephone lines will be limited to the first 50 groups and/or individuals who register. FDA may limit the number of participants from each organization, as well as the total number of participants, based on current space limitations.

If you would like to participate, please send your name, email address, telephone number and affiliation information to Randi Clark (randi.clark@fda.hhs.gov) by no later than September 7. Registrants will receive confirmation and additional information about the teleconference once registration has been received and accepted.

FDA looks forward to your participation.

Thank you,

Dominic Cirincione

August 17, 2012